ABSTRACT
Objective To investigate the influence of intensified acid suppression scheme on operation-related clinical parameters, re-bleeding rate and laboratory indexes of elderly patients with ANVUGIB underwent endoscopic hemostasis. Methods 150 elderly patients with ANVUGIB underwent endoscopic hemostasis were chosen from June 2015 to June 2017 and randomly divided into control group (75 patients) with conventional dose of pantoprazole and observation group (75 patients) with intensified dose of pantoprazole; and the clinical efficacy, the disappeared time of spitting blood and melena, hemostasis time, total blood transfusion volume, hospitalization time, re-bleeding rate, conversion to open surgery rate, the levels of laboratory index in 24 h and 72 h after treatment and adverse reaction incidence of both groups were compared. Results The clinical total effects of observation group were significantly higher than that in control group (P < 0.05). The disappeared time of spitting blood and melena, hemostasis time,total blood transfusion volume, hospitalization time of observation group were significantly better than that in control group (P < 0.05). The re-bleeding rate and conversion to open surgery rate of observation group were significantly lower than that in control group (P < 0.05). The levels of laboratory index in 24 h and 72 h after treatment of observation group were significantly better than that in control group (P < 0.05). There was no significant difference in the adverse reaction incidence between the two groups (P > 0.05). Conclusion Intensified acid suppression scheme in the treatment of elderly patients with ANVUGIB undergoing endoscopic hemostasis can efficiently achieve hemostasis in early stage, relieve symptoms and signs, decrease the blood loss amount in perioperative period, reduce the conversion to open operation risk and be helpful to improve the levels of PCV and BUN.
ABSTRACT
<p><b>OBJECTIVE</b>To understand the relationship between the susceptibility to inflammatory bowel disease (IBD) and ATG16L1 gene single nucleotide polymorphism (SNP) site, rs2241880.</p><p><b>METHODS</b>Peripheral blood samples were collected from 80 IBD patients (including 40 with Crohn's disease and 40 with ulcerative colitis) and 50 healthy controls, and the genomic DNA was extracted from the white blood cells. Specific primers were designed according to the target gene sequence for PCR amplification of the target gene fragment, and the PCR products were purified followed by sequence analysis of the target region of ATG16L1 gene. The results of the sequence analysis were compared with the BenBank data to analyze the relationship between the allele gene polymorphisms and the susceptibility to Crohn's disease.</p><p><b>RESULTS</b>No significant differences were noted in the ATG16L1 gene SNP site rs2241880 polymorphisms among the patients with Crohn's disease, ulcerative colitis and the control subjects (Chi(2)=4.94, P=0.293).</p><p><b>CONCLUSION</b>ATG16L1 gene polymorphisms in the SNP site rs2241880 are not found to correlate to the susceptibility to Crohn's disease as reported in literature. The SNP site associated with Crohn's disease susceptibility identified in foreign populations does not seem to be identical with that in Chinese population.</p>